Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 17

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 1
Chunk 17
---
The
table below provides information about the Company’s revenue, significant segment expenses and other segment expenses.

 Schedule
of Segment Information

    2025  
    2024 

    Three Months Ended June 30, 

    2025  
    2024 
  
    Revenues 
    $—  
    $— 
  
    Less segment expenses: 

    Research and development 
     42,839  
     594,801 
  
    Related party travel costs 
     -  
     - 
  
    General and administrative 
     5,028,158  
     879,695 
  
    Loss from operations 
    $5,070,997  
     1,474,496 
  
    Plus: 

    Interest income (expense),net 
     22  
     25,493 
  
    Segment net loss 
    $(5,070,975) 
    $(1,449,003)

    2025  
    2024 

    Six Months Ended June 30, 

    2025  
    2024 
  
    Revenues 
    $—  
    $— 
  
    Less segment expenses: 

    Research and development 
     379,835  
     1,398,824 
  
    Related party travel costs 
     -  
     370,500 
  
    General and administrative 
     6,877,857  
     1,621,237 
  
    Loss from operations 
    $7,257,692  
     3,390,561 
  
    Plus: 

    Interest income (expense),net 
     7,974  
     (4,313,049)
  
    Segment net loss 
    $(7,249,718) 
    $(7,703,610)

Note
8. Subsequent Events

ATM
Offering 

On
July 18, 2025, Telomir Pharmaceuticals, Inc. (the “Company”), sold a total of 1,100,000 shares of its common stock, no par
value, in block sales to institutional investors, at an average price of $2.6045 per share (a premium to the prior day’s close),
through its at-the-market equity offering facility (the “Offering”). Gross proceeds from the Offering totaled approximately
$2.9